Trial in Alzheimers disease

Apodemus is currently performing a phase IIa trial in Alzheimers disease. The main part of the trial has been completed whereas the follow-up part is scheduled to end in June 2016. The results from the main part of the trial have been analysed. The outcome of the trial has been found to be inconclusive due to a large drop-out rate that made data difficult to interpret. In order to test the hypothesis properly Apodemus AB will assess whether to repeat the trial with a modification of its design. A decision to continue development or not will be taken shortly.